Aapro, M., A. Scherhag, and H. U. Burger. 2008. Effect of treatment with epoetin-β on survival, tumor progression, and thromboembolic events in patients with cancer: An updated meta-analysis of 12 randomised controlled studies including 2301 patients. British Journal of Cancer 99:14-22.
Bohlius, J., S. Langensiepen, G. Schwarzer, et al. 2005. Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis. Journal of the National Cancer Institute 97:489-498.
Hardee, M. E., M. O. Arcasoy, K. L. Blackwell, et al. 2006. Erythropoietin biology in cancer. Clinical Cancer Research 12:332-339.
Jones, M., B. Schenkel, J. Just, et al. 2004. Epoetin Alfa improves quality of life in patients with cancer: Results of a meta-analysis. Cancer 101:1720-1732.
Oster, H. S., M. Hoffman, S. Pruchti-Sagiv, et al. 2006. Erythropoietin in clinical practice: Current use, effect on survival, and future directions. Israel Medical Association Journal 8:703-706.
Pronzato, P. 2006. Cancer-related anaemia management in the 21st century. Cancer Treatments Reviews 32:S1-S3.
Rizzo, J. D., M. R. Somerfield, K. L. Hagerty, et al. 2008. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. Journal of Clinical Oncology 26:132-149.
Straus, D. J. 2005. Treatment of anemia with erythropoietic agents in patients with hematologic malignancies. Supportive Cancer Therapies 2:215-224.
Straus, D. J., M. A. Testa, B. J. Sarokhan, et al. 2006. Quality-of-life and health benefits of early treatment of mild anemia: A randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 107:1909-1917.